Pacgen Biopharmaceuticals files for initial public offering

By Jennifer Chiou

New York, Aug. 30 - Pacgen Biopharmaceuticals Corp. said it filed a preliminary prospectus for an initial public offering with the securities regulatory authorities in British Columbia, Alberta, Saskatchewan, Manitoba and Ontario.

According to a company news release, the offering will be made through Canaccord Capital Corp. and Jennings Capital Inc.

Based in Vancouver, B.C., Pacgen is a biotechnology company specializing in peptide therapeutics for infectious diseases and immune system regulations. The company has drug candidates for the treatment of oral candidiasis in HIV-infected patients as well as for acute respiratory distress syndrome.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.